AIDS vaccine approaches a clinical trial after passing a key safety test

Plans to transfer HIV to the clinical trial took a major step in this direction, after a team of researchers developed a weak form of AIDS vaccine that appears to be as effective as other strains or stronger forms. In recent years, scientists have developed the simian immunodeficiency virus SIV vaccine, which is very similar to HIV, but infects monkeys more than humans; it belongs to a group of common herpes or herpes viruses that generate SIV proteins.

Previous studies have shown that the vast majority of rhesus monkeys who took the vaccine were resistant to SIV because their immune systems learned to counter the proteins of the virus.

However, any vaccine must be weakened before it is applied to humans to prevent its spread in the body, as the unweakened CMV virus can be very dangerous, especially in people with weakened immune systems or pregnant women.

In order to modify the virus, researchers deleted a gene called RH110, which stopped the virus’ ability to clone itself and stop its ability to reproduce through a process called the lytic cycle.

This form of AIDS vaccine, a weakened vaccine, was found to be 1000 times less common than the unweakened version, and its presence in monkey body secretions was also not observed or could not be transmitted between individuals.

In essence, this form of vaccine provided the same level of protection as other stronger forms, and was able to eliminate the SIV virus in 59% of monkeys, and its effects were also long-lasting, with 9 out of 12 SIV-resistant to SIV remaining for three years.

The results were then published in two separate pages in the journal Science Translational Medicine.

Although human clinical trials take several years, this research represents a major step forward in creating a safe and effective HIV vaccine.

Add Comment